nasopharyngeal carcinoma
Conditions
Interventions
Experimental group:Lenalidomide and chemoradiotherapy
Sponsors
Cancer Prevention and Treatment Center of Guigang People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. histopathologically confirmed and untreated nasopharyngeal carcinoma patients; 2. Aged 18 to 70 years old; 3. body status ECOG 0~2; 4. normal blood biochemical indexes, normal liver and kidney functions; 5. patients and their families have given informed consent.
Exclusion criteria
Exclusion criteria: 1. Participated in other clinical trials in the last 3 months; 2. Secondary lymphoma; 3. Transforming lymphoma; 4. Primary central nervous system lymphoma or lymphoma invades central nervous system; 5. Allergic to any research drug; 6. Combined with other malignancies, except for cured basal cell carcinoma; 7. patients with active infections who need treatment; 8. Organ dysfunction such as malignant hypertension, heart failure, dilated cardiomyopathy, unstable angina pectoris, or myocardial infarction occurring within 6 months, renal insufficiency (Cr >1.5 ULN), abnormal liver function (AST / ALT >2.5 ULN or BIL >2.0mg/dl); 9. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival;Overall survival;Distance metastasis free survival;Relapse-free survival;Albumin;RTOG scale;Body weight;Toxicity;QLICP-HN (V1.0) scale; | — |
Countries
China
Contacts
Public ContactHaizhen Yi
Cancer Prevention and Treatment Center of Guigang People's Hospital
Outcome results
None listed